Pharmaceutical Business review is using cookies

ContinueLearn More

Novartis AIN457 demonstrates efficacy in psoriasis treatment

Novartis has reported positive data from three Phase II trials which tested the efficacy of AIN457 (secukinumab) to treat moderate-to-severe plaque psoriasis.

AIN457 is a fully human, targeted monoclonal antibody that specifically binds to and neutralizes interleukin-17A (IL-17A), an inflammatory cytokine implicated in many immune-mediated diseases, including psoriasis.

The three double-blind, parallel group, placebo-controlled Phase II studies tested AIN457 in different doses and administration regimens.

In one study, 81% of patients receiving AIN457 150mg subcutaneously once a month experienced at least a 75% improvement of psoriasis signs and symptoms as measured by PASI (Psoriasis Area and Severity Index), as compared to 9% for placebo at week 12.

In another study, 83% of patients who were given an intravenous starting dose of AIN457 experienced at least a 75% improvement of symptoms vs 10% for placebo.

In the third study, AIN457 in the first month was beneficial to 55% of patients vs 2% for placebo at week 12.